AdAlta partner gets China approval for armored CAR-T mesothelioma therapy
Shanghai Cell Therapy Group, AdAlta’s co-development partner, received approval to provide BZDS1901 first-in-class armored CAR-T therapy to eligible patients with advanced mesothelioma under China’s special access scheme.
AdAlta ASX:1AD co-development partner Shanghai Cell Therapy Group has received approval to provide BZDS1901 first-in-class, armored CAR-T cell therapy to eligible patients with advanced mesothelioma.The approval, which falls under a special access scheme in China’s Hainan Boao Lecheng international…